Primary Immunodeficiencies in Costa Rican Adults
CASE SERIES OF PRIMARY IMMUNODEFICIENCIES IN ADULTS DIAGNOSED IN TWO HOSPITALS OF THE TERTIARY LEVEL OF CARE OF THE COSTA RICAN SOCIAL SECURITY Fund, 2017-2018
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
San José, Costa Rica, 00000
- Hospital Calderon Guardia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients from adult primary immunodeficiency clinics will be included.
Exclusion Criteria:
- Patients with HIV
- Proven secondary immunodeficiencies.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical manifestations of all adult patients diagnosed with primary and idiopathic immune defects
Time Frame: 1 year
|
Describe the clinical manifestations of all adult patients diagnosed with primary and idiopathic immune defects attended in the primary immunodeficiency clinics of the Hospitals Mexico and Dr. Rafael Ángel Calderón Guardia during the study period.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
characterization of immunodeficient patients
Time Frame: 1 year
|
Characterize immunodeficient patients using sociodemographic and health variables.
|
1 year
|
|
Concordances between clinical manifestations and literature
Time Frame: 1 year
|
•Establish concordances between the clinical manifestations of the group of patients under study with those described in the literature according to the different pathologies.
|
1 year
|
|
organic complications
Time Frame: 1 year
|
Record organic complications secondary to immunodeficiency status.
|
1 year
|
|
type and degree of immunodeficiency
Time Frame: 1 year
|
Differentiate the type and degree of immunodeficiency of each patient.
|
1 year
|
|
pathonges that cause infectious
Time Frame: 1 year
|
Report isolated pathogens that cause infectious manifestations in patients.
|
1 year
|
|
bacteria present in upper airways
Time Frame: 1 year
|
•Report the colonizing bacteria present in the cultures of the upper airways of the patients requested in the initial approach.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- R017-SABI-00148.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.